AHA letter to HRSA on 340B Program and Kalderos Issue

The AHA October 30, sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program. View the entire letter under Key Resources.